Dr Shore on the Rationale for the EMBARK Trial in Nonmetastatic Prostate Cancer
May 10th 2023Neal Shore, MD, FACS, discusses the rationale for the phase 3 EMBARK trial investigating enzalutamide plus leuprolide in patients with nonmetastatic hormone-sensitive prostate cancer with high-risk biochemical recurrence.
Read More